Administration af Zenapax hæmmer IL- 2- medieret aktivering af lymfocytter, en kritisk pathway i det cellulære immunrespons som er involveret i allotransplantat rejektion.
Administration of Zenapax inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.